# EDGAR Filing Document

**Accession Number:** 0001828318
**File Stem:** 0001828318-26-000010
**Filing Date:** 2026-2
**Character Count:** 24004
**Document Hash:** 8f5872c43040a385f7b0457dcc1bc0be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001828318-26-000010.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0001828318-26-000010

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**REFERENCES 429**: 333-259730

**REFERENCES 429**: 333-267050

**REFERENCES 429**: 333-273847

**REFERENCES 429**: 333-281261

**REFERENCES 429**: 333-285209

**FILED AS OF DATE**: 20260225

**DATE AS OF CHANGE**: 20260225

**EFFECTIVENESS DATE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enovix Corp
- **CENTRAL INDEX KEY:** 0001828318
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 853174357
- **FISCAL YEAR END:** 1228

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293753
- **FILM NUMBER:** 26679672

**BUSINESS ADDRESS:**
- **STREET 1:** 3501 W. WARREN AVENUE
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510 695-2350

**MAIL ADDRESS:**
- **STREET 1:** 3501 W. WARREN AVENUE
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Rodgers Silicon Valley Acquisition Corp
- **DATE OF NAME CHANGE:** 20201014

**As filed with the U.S. Securities and Exchange Commission on February 25, 2026**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER THE SECURITIES ACT OF 1933**

**Enovix Corporation**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **85-3174357** |
| (State or other jurisdiction of <br>incorporation or organization) | (I.R.S. Employer <br>Identification No.) |

---

**3501 W. Warren Avenue<br>Fremont, CA 94538**<br> (Address of principal executive offices, including zip code)

**Enovix Corporation 2021 Equity Incentive Plan**

**Enovix Corporation 2021 Employee Stock Purchase Plan**

(Full titles of the plans)

**Arthi Chakravarthy**

**Chief Legal Officer**

**Enovix Corporation**

**3501 W. Warren Avenue**

**Fremont, CA 94538**

**Telephone: (510) 695-2350**

(Name, address and telephone number, including area code, of agent for service)

*Copies to:*

---

| |
|:---|
| **Michael Penney** |
| **Arnold & Porter Kaye Scholer LLP** |
| **250 West 55th Street** |
| **New York, NY 10019** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;⌧ | Accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;◻ |
| Non-accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;◻ | Smaller reporting company&nbsp;&nbsp;&nbsp;&nbsp;◻ |
| | Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

------

**EXPLANATORY NOTE**

Enovix Corporation (the "***Registrant***") is filing this Registration Statement for the purpose of registering (i) an additional 8,662,339 shares of the Registrant's common stock, par value $0.0001 per share ("***Common Stock***"), to be issued pursuant to the Registrant's 2021 Equity Incentive Plan (the "***2021 Plan***") and (ii) an additional 2,000,000 shares of Common Stock to be issued pursuant to the Registrant's 2021 Employee Stock Purchase Plan (the "***2021 ESPP***"). The shares of Common Stock being registered pursuant to this Registration Statement are the same class as, and in addition to, other securities for which the Registration Statements on Form S-8 were filed with the Securities and Exchange Commission (the "***SEC***") on <u>[September 23, 2021 (File No. 333-259730)](https://www.sec.gov/Archives/edgar/data/1828318/000119312521279645/d184479ds8.htm)</u>, <u>[August 24, 2022 (File No. 333-267050)](https://www.sec.gov/Archives/edgar/data/1828318/000182831822000035/enovix-s820220816evergreen.htm)</u>, <u>[August 9, 2023 (File 333-273847)](https://www.sec.gov/Archives/edgar/data/1828318/000182831823000171/0001828318-23-000171-index.htm)</u>, <u>[August 5, 2024 (File 333-281261)](https://www.sec.gov/Archives/edgar/data/1828318/000162828024034818/envx-s820240805evergreenin.htm)</u>, and <u>[February 25, 2025](https://www.sec.gov/Archives/edgar/data/1828318/000182831825000059/envx-s820250225evergreenin.htm)[(File No. 333-285209)](https://www.sec.gov/Archives/edgar/data/1828318/000182831825000059/envx-s820250225evergreenin.htm)</u> (collectively, the "***Prior Registration Statements***"). Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2021 Plan and the 2021 ESPP, as applicable, are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

**PART II**

**ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE**

The Registrant is incorporating by reference into this Registration Statement the filings listed below and any additional documents that the Registrant may file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), after the date of this Registration Statement, but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, except the Registrant is not incorporating by reference any information that is not deemed to be "filed" under Section 18 of the Exchange Act or otherwise subject to the liabilities of that section (including documents or information deemed furnished pursuant to Item 2.02 or Item 7.01 of any Current Report on Form 8-K and corresponding information furnished under Item 9.01 as an exhibit thereto), unless the report or filing containing such information indicates that the information is to be considered "filed" under the Exchange Act or is to be incorporated by reference in this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;the Registrant's Annual Report on <u>[Form](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001828318/000182831826000006/envx-20251228.htm)[10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001828318/000182831826000006/envx-20251228.htm)</u> for the fiscal year ended December 28, 2025 filed with the SEC on February 25, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;the Registrant's Current Report on <u>[F](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001828318/000162828026002494/envx-20260119.htm)[orm 8-](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001828318/000162828026002494/envx-20260119.htm)[K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001828318/000162828026002494/envx-20260119.htm)</u> filed with the SEC on January 20, 2026 (only with respect to Item 5.02 thereof); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;the description of the Registrant's Common Stock that is contained in <u>[Exhibit 4.4](https://www.sec.gov/Archives/edgar/data/1828318/000095017022004614/envx-ex4_4.htm)</u> to the Registrant's Annual Report on Form 10-K for the fiscal year ended January 2, 2022 filed with the SEC on March 25, 2022, including any amendment or supplements thereto.

Any statement contained in this Registration Statement, or in a document incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded to the extent that a statement contained herein, or in any subsequently filed document that also is incorporated or deemed to be incorporated by reference herein, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

**ITEM 8.&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br>**Number** | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit**<br>**Number** | **Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation of Enovix Corporation](https://www.sec.gov/Archives/edgar/data/0001828318/000119312521218701/d49082dex31.htm).</u> | 8-K | 001-39753 | 3.1 | July 19, 2021 |
| 4.2 | <u>[Amended and Restated Bylaws of Enovix Corporation](https://www.sec.gov/Archives/edgar/data/1807707/000110465921010348/tm214570d1_ex3-2.htm).</u> | 8-K | 001-39753 | 3.2 | July 19, 2021 |
| 4.3 | <u>[Specimen Common Stock Certificate.](https://www.sec.gov/Archives/edgar/data/0001828318/000110465921082889/tm217682d14_ex4-5.htm)</u> | S-4/A | 333-253976 | 4.5 | June 21, 2021 |
| 5.1\* | <u>[Opinion of Arnold & Porter Kaye Scholer LLP.](envx-s820260225ex51arnoldp.htm)</u> |  |  |  |  |
| 23.1\* | <u>[Consent of Deloitte & Touche LLP, independent registered public accounting firm.](envx-s820260225ex231dtcons.htm)</u> |  |  |  |  |
| 23.2\* | <u>[Consent of Arnold & Porter Kaye Scholer LLP (included in Exhibit 5.1 hereto).](envx-s820260225ex51arnoldp.htm)</u> |  |  |  |  |
| 24.1\* | <u>[Power of Attorney (included on signature page hereto).](#i870e5d23303944aeb29c89987e2f8f02_13)</u> |  |  |  |  |
| 99.1 | <u>[2021 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/0001828318/000119312521218701/d49082dex102.htm)</u> | 8-K | 001-39753 | 10.2 | July 19, 2021 |
| 99.2 | <u>[Form of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice under the 2021 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1828318/000110465921063953/tm217682d5_ex10-11.htm)</u> | S-4/A | 333-253976 | 10.11 | June 21, 2021 |
| 99.3 | <u>[Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1828318/000110465921063953/tm217682d5_ex10-12.htm)</u> | S-4/A | 333-253976 | 10.12 | June 21, 2021 |
| 99.4 | <u>[Forms of Restricted Stock Unit Grant Notice for Long-Term Incentive Plan Award and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan](https://www.sec.gov/Archives/edgar/data/1828318/000182831822000026/envx-q220220703exx1012021e.htm)</u>. | 10-Q | 001-39753 | 10.1 | August 16, 2022 |
| 99.5 | <u>[Form of Global RSU Award Grant Notice under the 2023 Long-Term Incentive Plan](https://www.sec.gov/Archives/edgar/data/1828318/000162828023016122/envx-q120230402exx107formo.htm)</u> | 10-Q | 001-39753 | 10.7 | May 5, 2023 |
| 99.6 | <u>[2021 Employee Stock Purchase Plan.](https://www.sec.gov/Archives/edgar/data/0001828318/000119312521218701/d49082dex105.htm)</u> | 8-K | 001-39753 | 10.5 | July 19, 2021 |
| 99.7 | <u>[Form of 2024 Performance Stock Unit Award Grant Notice and Agreement under the 2021 Equity Incentive Plan](https://www.sec.gov/Archives/edgar/data/1828318/000182831824000066/envx-q120240331ex102prsugr.htm)</u> | 10-Q | 001-39753 | 10.2 | May 7, 2024 |
| 107\* | <u>[Filing Fee Table.](exfilingfees.htm)</u> |  |  |  |  |

---

<u><br></u>

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on this 25th day of February, 2026.

---

| | |
|:---|:---|
|  | **ENOVIX CORPORATION** |
| By: | /s/ Raj Talluri |
|  | Dr. Raj Talluri |
|  | President and Chief Executive Officer |

---

------

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dr. Raj Talluri and Ryan Benton, and each of them, as their true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |

---

---

| | | |
|:---|:---|:---|
| /s/ Raj Talluri | President and Chief Executive Officer and Director<br>(*Principal Executive Officer*) | February 25, 2026 |
| Dr. Raj Talluri | President and Chief Executive Officer and Director<br>(*Principal Executive Officer*) | February 25, 2026 |

---

---

| | | |
|:---|:---|:---|
| /s/ Ryan Benton | Chief Financial Officer <br>(Principal Financial Officer and Principal Accounting Officer) | February 25, 2026 |
| Ryan Benton | Chief Financial Officer <br>(Principal Financial Officer and Principal Accounting Officer) | February 25, 2026 |

---

---

| | | |
|:---|:---|:---|
| /s/ Thurman John Rodgers | Chairman of the Board of Directors | February 25, 2026 |
| Thurman John Rodgers | Chairman of the Board of Directors | February 25, 2026 |

---

---

| | | |
|:---|:---|:---|
| /s/ Betsy Atkins | Director | February 25, 2026 |
| Betsy Atkins | Director | February 25, 2026 |

---

---

| | | |
|:---|:---|:---|
| /s/ Pegah Ebrahimi | Director | February 25, 2026 |
| Pegah Ebrahimi | Director | February 25, 2026 |

---

---

| | | |
|:---|:---|:---|
| /s/ Bernard Gutmann | Director | February 25, 2026 |
| Bernard Gutmann | Director | February 25, 2026 |

---

---

| | | |
|:---|:---|:---|
| /s/ Joseph Malchow | Director | February 25, 2026 |
| Joseph Malchow | Director | February 25, 2026 |

---

---

| | | |
|:---|:---|:---|
| /s/ John Daniel McCranie | Director | February 25, 2026 |
| John Daniel McCranie | Director | February 25, 2026 |

---

---

| | | |
|:---|:---|:---|
| /s/ Gregory Reichow | Director | February 25, 2026 |
| Gregory Reichow | Director | February 25, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**EX-FILING FEES (Exhibit 107)**

**CALCULATION OF FILING FEE TABLE**

**Form S-8** (Form Type)

**Enovix Corporation** (Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered** <sup>(1)</sup> | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Stock, par value $0.0001 per share, Enovix Corporation 2021 Equity Incentive Plan | Other <sup>(2)</sup> | 8662339 <sup>(3)</sup> | $5.95 <sup>(2)</sup> | $51540917.05 | 0.0001381 | $7117.80 |
| Equity | Common Stock, par value $0.0001 per share, Enovix Corporation 2021 Employee Stock Purchase Plan | Other <sup>(4)</sup> | 2000000 <sup>(5)</sup> | $5.06 <sup>(4)</sup> | $10120000.00 | 0.0001381 | $1397.57 |
| Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  | $61660917.05 |  | $8515.37 |
| Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  |
| Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $8515.37 |

---

_______

(1)&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "***Securities Act***"), this Registration Statement shall also cover any additional shares of common stock, par value $0.0001 per share ("***Common Stock***"), of Enovix Corporation (the "***Registrant***") that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected that results in an increase to the number of outstanding shares of Common Stock, as applicable.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Estimated in accordance with Rule 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of $5.95 per share, which is the average of the high and low prices of Common Stock, as reported on the Nasdaq Global Select Market on February 20, 2026.

(3)&nbsp;&nbsp;&nbsp;&nbsp;Represents an automatic annual increase on January 1, 2026 to the number of shares available for issuance pursuant to the Registrant's 2021 Equity Incentive Plan (the "***2021 Plan***") in an amount equal to 4% of the total number of shares of Common Stock outstanding on December 31 of the preceding year, which annual increase is provided by the 2021 Plan.

(4)&nbsp;&nbsp;&nbsp;&nbsp;Estimated in accordance with Rule 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of the average of the high and low prices of Common Stock, as reported on the Nasdaq Global Select Market on February 20, 2026, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the Registrant's 2021 Employee Stock Purchase Plan (the "***2021 ESPP***").

(5)&nbsp;&nbsp;&nbsp;&nbsp;Represents an automatic annual increase on January 1, 2026 to the number of shares available for issuance pursuant to the 2021 ESPP in an amount equal to the lesser of (i) 1% of the total number of shares of Common Stock outstanding on December 31 of the preceding year and (ii) 2,000,000 shares of Common Stock, which annual increase is provided by the 2021 ESPP.

## Exhibit 5.1

**Exhibit 5.1**

![imagea.jpg](imagea.jpg)

February 25, 2026

Enovix Corporation 3501 W. Warren Avenue Fremont, CA 94538

<br>Re:&nbsp;&nbsp;&nbsp;&nbsp;Enovix Corporation - Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to Enovix Corporation, a Delaware corporation (the "**Company**"), in connection with the preparation of the Company's registration statement on Form S-8 (the "**Registration Statement**") to be filed with the U.S. Securities and Exchange Commission (the "**Commission**") on or about the date hereof, relating to the registration under the Securities Act of 1933, as amended (the "**Securities Act**"), of 10,662,339 shares (the "**Shares**") of the Company's common stock, par value $0.0001 per share ("**Common Stock**"), consisting of (i) 8,662,339 shares of Common Stock issuable pursuant to the Company's 2021 Equity Incentive Plan (the "**2021 Plan**") and (ii) 2,000,000 shares of Common Stock issuable pursuant to the Company's 2021 Employee Stock Purchase Plan (the "**2021 ESPP**," together with the 2021 Plan, the "**Plans**").

This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act.

In rendering the opinions set forth below, we have examined and relied upon such certificates, corporate records, agreements, instruments and other documents, and examined such matters of law, that we considered necessary or appropriate as a basis for the opinions. In our examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies, the authenticity of the originals of such latter documents, that all parties to such documents (other than the Company) had the power, corporate or other, to enter into and perform all obligations thereunder, that all such documents have been duly authorized by all requisite action, corporate or other, and duly executed and delivered by all parties thereto (other than the Company) and that all such documents constitute the valid and binding obligation of each party thereto (other than the Company) enforceable against each such party in accordance with their terms. As to any facts material to the opinions expressed herein that we did not independently establish or verify, we have relied upon oral or written statements and representations of officers and other representatives of the Company and others.

**Arnold & Porter Kaye Scholer LLP**<br>250 West 55th Street **\|** New York, NY 10019-9710 **\| www.arnoldporter.com**<br>

------

![imagea.jpg](imagea.jpg)

Based upon the foregoing and subject to the assumptions, qualifications and limitations set forth herein, we are of the opinion that the Shares have been duly authorized, and when issued and delivered by the Company in connection with awards granted under the Plans in accordance with the terms and conditions set forth in the Plans, subject to the full payment of the exercise price therefor (if any), the Shares will be validly issued, fully paid and non-assessable.

The opinions expressed herein are based solely upon the General Corporation Law of the State of Delaware (including the statutory provisions contained therein, the applicable rules and regulations underlying these provisions and reported judicial decisions interpreting the foregoing). We express no opinion herein as to any other laws, statutes, rules, regulations or ordinances.

The opinions set forth above are limited to the matters expressly set forth herein, and no opinion is implied or may be inferred beyond the matters expressly stated. The foregoing opinions are rendered as of the date hereof, and we assume no obligation to update such opinions to reflect any acts, events, facts or circumstances occurring after the date hereof or which may hereafter come to our attention, or any change in the law which may hereafter occur.

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are experts within the meaning of the Securities Act or the rules and regulations of the Commission or that this consent is required by Section 7 of the Securities Act.

Very truly yours,

/s/ Arnold & Porter Kaye Scholer LLP

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated February 25, 2026, relating to the financial statements of Enovix Corporation and the effectiveness of Enovix Corporation's internal control over financial reporting, appearing in the Annual Report on Form 10-K of Enovix Corporation for the year ended December 28, 2025.

/s/ Deloitte & Touche LLP

San Jose, California

February 25, 2026

<br>